Heaney, L. G., Busby, J., Hanratty, C. E., Djukanovic, R., Woodcock, A., Walker, S. M., . . . Pavord, I. D. (2021). Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: A multicentre, single-blind, parallel group, randomised controlled trial. The lancet respiratory medicine, 9(1), 57. https://doi.org/10.1016/S2213-2600(20)30397-0
Citace podle Chicago (17th ed.)Heaney, Liam G., et al. "Composite Type-2 Biomarker Strategy Versus a Symptom-risk-based Algorithm to Adjust Corticosteroid Dose in Patients with Severe Asthma: A Multicentre, Single-blind, Parallel Group, Randomised Controlled Trial." The Lancet Respiratory Medicine 9, no. 1 (2021): 57. https://doi.org/10.1016/S2213-2600(20)30397-0.
Citace podle MLA (9th ed.)Heaney, Liam G., et al. "Composite Type-2 Biomarker Strategy Versus a Symptom-risk-based Algorithm to Adjust Corticosteroid Dose in Patients with Severe Asthma: A Multicentre, Single-blind, Parallel Group, Randomised Controlled Trial." The Lancet Respiratory Medicine, vol. 9, no. 1, 2021, p. 57, https://doi.org/10.1016/S2213-2600(20)30397-0.